Publikasi Scopus FKUI Tahun 2010 s/d 2020 (data Per 3 Februari 2021)

Sheu W.H.-H., Rosman A., Mithal A., Chung N., Lim Y.T., Deerochanawong C., Soewondo P., Lee M.-K., Yoon K.-H., Schnell O.
55664745400;37561779700;7004084666;7102914582;7402565417;6603729159;23475336100;7409120503;7401607502;7006418720;
Addressing the burden of type 2 diabetes and cardiovascular disease through the management of postprandial hyperglycaemia: An Asian-Pacific perspective and expert recommendations
2011
Diabetes Research and Clinical Practice
92
3
312
321
25
Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan; National Heart Institute, Kuala Lumpur, Malaysia; Division of Endocrinology and Diabetes, Medanta Medicity, Gurgaon, Delhi NCR, India; Yonsei University College of Medicine, Seoul 120-752, South Korea; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Diabetes and Endocrinology Unit, Rangsit Medical School, Rajavithi Hospital, Bangkok, Thailand; Division of Endocrinology and Metabolism, Department of Internal Medicine, Cipto Mangunkusumo Hospital, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; Department of Endocrinology and Metabolism, Seoul Saint Mary's Hospital, The Catholic University of Korea, South Korea; Diabetes Research Institute of the Diabetes Research Group, Helmholtz Center, Munich, Germany
Sheu, W.H.-H., Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan; Rosman, A., National Heart Institute, Kuala Lumpur, Malaysia; Mithal, A., Division of Endocrinology and Diabetes, Medanta Medicity, Gurgaon, Delhi NCR, India; Chung, N., Yonsei University College of Medicine, Seoul 120-752, South Korea; Lim, Y.T., Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Deerochanawong, C., Diabetes and Endocrinology Unit, Rangsit Medical School, Rajavithi Hospital, Bangkok, Thailand; Soewondo, P., Division of Endocrinology and Metabolism, Department of Internal Medicine, Cipto Mangunkusumo Hospital, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Lee, M.-K., Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; Yoon, K.-H., Department of Endocrinology and Metabolism, Seoul Saint Mary's Hospital, The Catholic University of Korea, South Korea; Schnell, O., Diabetes Research Institute of the Diabetes Research Group, Helmholtz Center, Munich, Germany
The world is facing an epidemic of cardiovascular disease (CVD) and type 2 diabetes, with populations in low- to middle-income countries, including many in the Asia Pacific (AP) region, being disproportionately affected. Emerging data identify postprandial hyperglycaemia (PPHG) as an important predictor of CVD, and several professional bodies, including the International Diabetes Federation, have issued guidelines on the management of PPHG in type 2 diabetes. Guidance on how international recommendations could be implemented in Asian populations is currently lacking. Therefore, a panel of experts from the AP region convened to consider the current status of PPHG and CVD in the region, and to develop recommendations for clinical practice. The group concluded that improved awareness of the impact of PPHG on CVD risk, among clinicians and the general public, and more widespread use of routine screening for PPHG, using oral glucose tolerance testing in those without recognised diabetes, are required. Additionally, frequent meal-based testing and effective PPHG management are essential to the management of IGT and type 2 diabetes. © 2011 Elsevier Ireland Ltd.
Asia; Cardiovascular disease; Postprandial hyperglycaemia; Type 2 diabetes
acarbose; alpha glucosidase inhibitor; glibenclamide; glutamine; hemoglobin A1c; insulin; insulin glargine; metformin; nateglinide; pioglitazone; repaglinide; rosiglitazone; troglitazone; valsartan; voglibose; atherosclerosis; blood glucose monitoring; cardiovascular disease; cardiovascular risk; clinical practice; glucose blood level; health service; human; hyperglycemia; impaired glucose tolerance; insulin resistance; lowest income group; non insulin dependent diabetes mellitus; oral glucose tolerance test; pathogenesis; pregnancy diabetes mellitus; prevalence; primary health care; review; screening test; Asia; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hyperglycemia
01688227
DRCPE
21605924
Review
Q1